Direxion Daily LLY Bull 2X ETFELIL

Direxion launched the Daily LLY Bull 2X Shares-ticker ELIL-on the Nasdaq exchange in 2024, giving traders a 2× concentrated, reset-daily bet on the closing price of Eli Lilly & Co. The fund is not a diversified basket; it is a single-stock turbocharged wager that resets every session, which means compounding can work for you or against you before you finish your morning coffee. (source: Nasdaq market activity for ELIL, https://www.nasdaq.com/market-activity/etf/elil)

ELIL’s mandate is explicit: “daily concentrated investment results (before fees and expenses) that correspond to two times (2×) the daily performance of the LLY Index,” which is simply the closing price of Eli Lilly shares. There is no sector diversification, no multi-name hedge, and no escape clause if Lilly’s headline risk turns south. The issuer’s marketing calls it “strategic exposure,” but the filing calls it a 2× concentrated daily index fund, and the market calls it a high-beta playground. (source: SEC EDGAR fund search for ELIL, https://www.sec.gov/edgar/search/#/q=ELIL)

The fund’s expense ratio is 0.95 % per annum, deducted daily, which FINRA’s Fund Analyzer confirms. That fee is levied whether the fund doubles or drops; it does not care about the drama. For comparison, plain-vanilla S&P 500 ETFs charge nearer 0.03 %, so ELIL’s toll is thirty times heavier for a concentrated, single-stock bet. The issuer’s pitch decks omit the fee’s compounding effect, focusing instead on headline “bullish exposure.” (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

The Nasdaq page for ELIL lists real-time quotes, market-cap, and volume, but it does not explain why the 2× leverage will compound in your favour any more than it explains why the fund’s top holding is Lilly itself. The page is a mirror: it shows the wrapper’s plumbing, not the wisdom of the wager. (source: Nasdaq market activity for ELIL, https://www.nasdaq.com/market-activity/etf/elil)

What remains unproven is whether the daily reset will reward disciplined traders over weeks or months; academic papers on concentrated daily resets caution that even small drawdowns can erase the expected compounding benefit. The SEC filing confirms the rulebook; the market decides who reads it. (source: SEC EDGAR fund search for ELIL, https://www.sec.gov/edgar/search/#/q=ELIL)

If you want thematic exposure to Eli Lilly with leverage and daily reset, ELIL delivers the mechanism. If you want diversification, liquidity, or low fees, the fund’s mandate and fee schedule say otherwise. The tension sits in the gap between the glossy brochure and the bare-bones filing, where the issuer’s marketing meets the SEC’s rulebook. (source: Nasdaq market activity for ELIL, https://www.nasdaq.com/market-activity/etf/elil)